YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provides earnings guidance for the year ending 31 December 2019. The Group expected that the Company will record a revenue of approximately RMB 6,220 million and approximately RMB 1,780 million for the year ended 31 December 2019 and the three months from 1 October 2019 to 31 December 2019 respectively, representing an increase of approximately 145% and approximately 125% as compared to the year ended 31 December 2018 and the three months from 1 October 2018 to 31 December 2018 respectively.